B
Bull
Bull · 25%PRTC
$17.61
Precio del escenario
$17.420
+0.347 (+1.99%)Al cierre
Loading chart…
- High
- 17.840
- Open
- 17.435
- VWAP
- 17.50
- Vol
- 7.18K
- Mkt Cap
- 586.33M
- Low
- 17.250
- Amount
- 125.62K
- EV/EBITDA, TTM
- 0.00
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
AI analysis of PureTech Health PLC (PRTC)
holdPureTech Health PLC is not a clear buy right now for a beginner long-term investor, even with $50,000-$100,000 to invest. The technicals are neutral-to-weak, there is no supportive options or news catalyst, proprietary trading signals are absent, and there is no fresh financial or analyst momentum to justify an immediate purchase. If you already own it, holding makes more sense than buying more today.
Métricas de valoración
The current forward P/E ratio for PureTech Health PLC (PRTC) is 0.00, compared to its 5-year average forward P/E of -4.82.
Alphio AI Price Scenarios for PRTC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PRTC
Cronología de eventos
Noticias
8.504-29seekingalphaPureTech Announces Voluntary Delisting Plan
9.504-29NewsfilterPureTech Health Reports 2025 Financial Results and Strategic Update
- 5.004-27Newsfilter
Seaport Therapeutics Appoints Dr. Sharon Mates to Board of Directors
8.504-11seekingalphaSeaport Therapeutics Files for IPO to Develop Neuropsychiatric Drugs
- 9.004-02Newsfilter
Deupirfenidone Shows Significant Efficacy in Idiopathic Pulmonary Fibrosis
PRTC FAQ — answered by Alphio AI
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
PureTech Health PLC is not a clear buy right now for a beginner long-term investor, even with $50,000-$100,000 to invest. The technicals are neutral-to-weak, there is no supportive options or news catalyst, proprietary trading signals are absent, and there is no fresh financial or analyst momentum to justify an immediate purchase. If you already own it, holding makes more sense than buying more today.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.